Shanghai Institute of Biological Products Co.

Shanghai, China

Shanghai Institute of Biological Products Co.

Shanghai, China

Time filter

Source Type

China's blood product market size mushroomed in 2016 under the impetus of liberalization of limited-price policy, price rises in varying degrees and lot release volume growth for blood products in 2015, estimated to reach RMB23.8 billion throughout the year, up 16.7% from 2015. China's blood product industry will develop at full speed boosted by downstream demand, accompanied by a steady rise in the number of plasma stations and consolidated profit margin improvement of plasma. The market size is expected to hit RMB47.5 billion in 2021. Main features of blood product industry in China 2016 are shown as below: 1. As plasma supply increases, supply-demand balance can be seen in 2025 China's plasma collection volume has been increasing over recent years driven by blood product price deregulation and accelerated establishment of new plasma stations. In 2016, 6,964 tons of plasma was collected in China, up 19.8% year on year. Despite continuous growth, plasma collection volume still cannot meet the ever-increasing market demand. In the future, China will see plasma collection volume shooting up propelled by a growing number of plasma collection stations and is expected to achieve balance between plasma supply and demand in 2025. 2. A steady increase in lot release volume of main products So far, Chinese blood products are still dominated by human albumin and human immunoglobulin for intravenous injection, which take an over 70% blood product market share. In 2016, human albumin and human immunoglobulin (pH4) for intravenous injection registered respective lot release volumes of 39.31 million bottles (10g/bottle) and 10.89 million bottles (2.5g/bottle), up 17.8% and 27.4% respectively year on year. In addition, lot release volumes of domestic blood products in short supply such as blood coagulation factor VIII, human immunoglobulin and human prothrombin complex also witnessed substantial growth in 2016, respectively 38.0%, 143.8% and 20%. 3. R&D efforts intensified for new products; comprehensive utilization of plasma to be raised At present, Chinese blood product enterprises can separate a maximum of 11 varieties of blood products from the plasma, 3-4 varieties for general firms, indicating an extremely low rate of comprehensive utilization of plasmas. To solve the problem, Chinese blood product enterprises are accelerating the development of new products, hoping to improve comprehensive utilization of plasma. Blood coagulation factor VIII, for example, Guizhou Taibang Biological Products Co., Ltd., Jiangxi Boya Bio-Pharmaceutical Co., Ltd., Beijing Tiantan Biological Products Co., Ltd., Zhenxing Biopharmaceutical & Chemical Co., Ltd., Wuhan Zhongyuan Ruide Biological Products Co., Ltd. etc. are actively conducting clinical trials of blood coagulation factor VIII and expected to achieve mass production in next two years. 4 Plasma-oriented pattern continues Blood product industry relies heavily on plasma materials - the number of plasma stations directly influences plasma collection volume, which then affects raw material supply of blood product enterprises. Therefore, the number of plasma stations and plasma collection volume determine corporate position in industry. There are over 30 blood product manufacturing enterprises in China, but only more than 20 are able to maintain normal production. Among them, Hualan Biological Engineering,Inc., Shanghai RAAS Blood Products Co., Ltd. and China Biologic Products, Inc. boast relatively high volume of plasma collection, altogether accounting for 39.6% of total plasma collections in 2016. The report highlights the following: - Analysis on development of China blood product industry, including status quo, policy environment, market supply & demand, market size, market structure and competition pattern; - Analysis on 8 market segments of China blood product industry, including development status, competition pattern and trends; - Analysis on 13 major enterprises, including operation, blood product business, etc.; - Summary & forecast and trends. - The Chinese Version of this Report is Available on Request. 1 Overview of Truck Industry 1.1 Definition and Classification 1.2 Introduction of Technologies 1.3 Latest Policies during 2016-2017 1.3.1 Enforcement of National V Emission Standards 1.3.2 GB1589 Standards and "921 New Reform" 1.3.3 Ban on Low-Speed Trucks 1.3.4 Compulsory Installation of ABS Device for Trucks 1.3.5 Yellow Label' Vehicle Elimination Continues 1.4 Self-driving and Connected Truck 1.4.1 Truck Self-driving 1.4.2 Truck Telematics 2 Truck Market as a Whole 2.1 Ownership 2.2 Production and Sales 2.2.1 Production 2.2.2 Sales 2.3 Market Structure 2.4 Import & Export 2.5 Competitive Pattern 3 Truck Market Segments 3.1 Heavy Truck 3.1.1 Production and Sales 3.1.2 Competitive Landscape 3.1.3 Natural Gas Heavy Truck 3.1.4 High-end Heavy Truck 3.2 Medium Truck 3.2.1 Production and Sales 3.2.2 Competitive Landscape 3.3 Light Truck 3.3.1 Production and Sales 3.3.2 Competitive Landscape 3.4 Mini Truck 3.4.1 Production and Sales 3.4.2 Competitive Landscape 5 Key Companies 5.1 FAW Jiefang Automotive Co., Ltd. 5.1.1 Profile 5.1.2 Production and Sales 5.1.3 Launch of New Products 5.1.4 Manufacturing Bases 5.1.5 Developments 5.2 China National Heavy Duty Truck Group Co., Ltd. (SINOTRUK) 5.2.1 Profile 5.2.2 Operation 5.2.3 Production and Sales 5.2.4 Heavy-duty Truck Business 5.3 Dongfeng Motor Corporation 5.3.1 Profile 5.3.2 Operation 5.3.3 Truck Business 5.3.4 Capacity Distribution 5.3.5 Developments 5.4 Beiqi Foton Motor Co., Ltd. 5.4.1 Profile 5.4.2 Operation 5.4.3 Heavy-duty Truck Business 5.4.4 Production Capacity 5.4.5 Progress in Launch of New Products 5.5 Shaanxi Automobile Group Co., Ltd. 5.5.1 Profile 5.5.2 Major Products 5.5.3 Heavy-duty Truck Business 5.5.4 Developments 5.6 Anhui Jianghuai Automobile Group Corp.,Ltd. 5.6.1 Profile 5.6.2 Operation 5.6.3 Production and Sales 5.6.4 Capacity Distribution 5.6.5 Developments 5.7 Hualing Xingma Automobile (Group) Co., Ltd. 5.7.1 Profile 5.7.2 Operation 5.7.3 Truck Business 5.7.4 Production and Sales 5.8 QingLing Motors (Group) Co., Ltd. 5.8.1 Profile 5.8.2 Operation 5.8.3 Truck Business 5.9 Jiangling Motors Co., Group 5.9.1 Profile 5.9.2 Jiangling Holdings Limited 5.9.3 Production and Sales 5.9.4 Capacity Distribution 5.9.5 Developments 5.10 SAIC GM Wuling (SGMW) 5.10.1 Profile 5.10.2 Key Business 5.10.3 Production and Sales 5.10.4 Manufacturing Bases 5.11 SAIC-IVECO Hongyan 5.11.1 Profile 5.11.2 Heavy-duty Truck Business 5.11.3 Sales Goal for 2017 5.12 Hubei Tri-Ring Special Vehicle Co., Ltd. 5.12.1 Profile 5.12.2 Truck Business 5.12.3 Production and Sales 5.12.4 Developments 5.13 XCMG Automobile 5.13.1 Profile 5.13.2 Heavy-duty Truck Business 5.13.3 Capacity Distribution 5.14 GAC HINO Motors Co., Ltd. 5.14.1 Profile 5.14.2 Operation 5.14.3 Heavy-duty Truck Business 5.14.4 Production Capacity 5.15 Zhejiang Feidie Automobile Manufacturing Co., Ltd. 5.15.1 Profile 5.15.2 Truck Business 5.16 Baotou Bei Ben Heavy-Duty Truck Co., Ltd. 5.16.1 Profile 5.16.2 Heavy-duty Truck Business 5.17 Shanxi Dayun Automobile Manufacturing Co., Ltd 5.17.1 Profile 5.17.2 Truck Business List of Charts - Classification of Truck (Freight Vehicle) - Applications of Truck - Technology Introduction of Key Heavy Truck Manufacturers in China - Schedule for Implementation of China's Motor Vehicle National V Emission Standards - Comparison of China's National IV and V Emission Standards - Standards for Identifying Oversize and Overload of Highway Freight Vehicles (in 6-axle case) - Policies and Regulations on Commercial Vehicle Telematics - Survey on Truck Telematics at Home and Abroad - China's Truck Ownership, 2010-2021E - China's Truck Output, 2010-2021E - China's Truck Sales, 2010-2021E - China's Truck Output and Growth Rate by Product, 2016-2017 - China's Truck Sales and Growth Rate by Product, 2016-2017 - China's Monthly Truck Exports, 2016 - China's Monthly Truck Imports, 2016 - Sales Volume and Market Share of Top10 Truck Manufacturers in China, 2016-2017 - China's Complete Heavy Truck Output and Sales Volume, 2010-2021E - China's Incomplete Heavy Truck Output and Sales Volume, 2010-2021E - China's Semi-trailer Towing Vehicle Output and Sales Volume, 2010-2021E - Sales Volume and Market Share of Top10 Complete Heavy Truck Manufacturers in China, 2016-2017 - Sales Volume and Market Share of Top10 Incomplete Heavy Truck Enterprises in China, 2016-2017 - Sales Volume and Market Share of Top10 Semi-trailer Towing Vehicle Manufacturers in China, 2016-2017 - Sales Volume of Natural Gas Heavy Trucks in China, 2014-2021E - Major Natural Gas Heavy Truck Manufacturers in China - High-end Heavy Trucks Launched by Enterprises in China - China's Complete Medium Truck Output and Sales Volume, 2010-2021E - China's Incomplete Medium Truck Output and Sales Volume, 2010-2021E - Sales Volume and Market Share of Top10 Complete Medium Truck Manufacturers in China, 2016-2017 - Sales Volume and Market Share of Top10 Incomplete Medium Truck Manufacturers in China, 2016-2017 - China's Complete Light Truck Output and Sales Volume, 2010-2021E - China's Incomplete Light Truck Output and Sales Volume, 2010-2021E - Sales Volume and Market Share of Top10 Complete Light Truck Manufacturers in China, 2016-2017 - Sales Volume and Market Share of Top10 Incomplete Light Truck Manufacturers in China, 2016-2017 - China's Complete Mini Truck Output and Sales Volume, 2010-2021E - China's Incomplete Mini Truck Output and Sales Volume, 2010-2021E - Sales Volume and Market Share of Top10 Complete Mini Truck Manufacturers in China, 2016-2017 - Automotive Industry Chain - Cost Structure of Truck Industry - Transmission Supply of Major Heavy Truck Manufacturers in China - China's Galvanized Sheet (Strip) Output and Sales Volume, 2010-2017 - China's (Shanghai) Galvanized Coil Price, 2014-2017 - China's Cold-rolled Thin Sheet Output and Sales Volume, 2010-2017 - China's (Shanghai, Tianjin, Guangzhou) Cold-rolled Coil Price, 2016-2017 - China's Natural Rubber Spot and Future Price, 2012-2017 - China's Investment in Fixed Assets, 2010-2017 - China's Investment in Real Estate Development, 2010-2017 - China's New Housing Start Area and Sales Area, 2005-2017 - China's Highway Freight Volume and Turnover, 2005-2017 - FAW Jiefang Automotive's Heavy Truck Output and Sales Volume, 2010-2017 - FAW Jiefang Automotive's Medium Truck Output and Sales Volume, 2010-2017 - FAW Jiefang Automotive's Light Truck Output and Sales Volume, 2010-2017 - FAW Jiefang Automotive's Mini Truck Output and Sales Volume, 2010-2017 - Main Natural Gas Trucks of FAW Jiefang Automotive - Main Truck Production Bases of FAW Group - Sinotruk's Revenue and Net Income, 2010-2016 - Sinotruk's Gross Margin, 2010-2016 - Sinotruk's Revenue Structure by Business, 2016 - Sinotruk's Heavy Truck Output and Sales Volume, 2010-2017 - Sinotruk's Medium Truck Output and Sales Volume, 2010-2017 - Sinotruk's Light Truck Output and Sales Volume, 2010-2017 - Sinotruk's Heavy Truck Product Family Genealogy - Sinotruk's Main Product Configuration - Dongfeng Motor's Revenue and Net Income, 2011-2016 - Dongfeng Motor's Gross Profit and Gross Margin, 2011-2016 - Dongfeng Motor's Revenue Breakdown by Business, 2015-2016 - Dongfeng Motor's Heavy Truck Output and Sales Volume, 2010-2017 - Dongfeng Motor's Medium Truck Output and Sales Volume, 2010-2017 - Dongfeng Motor's Light Truck Output and Sales Volume, 2010-2017 - Dongfeng Motor's Mini Truck Output and Sales Volume, 2010-2017 - Truck Capacity Distribution of Dongfeng Motor - Beiqi Foton Motor's Revenue and Net Income, 2010-2016 - Beiqi Foton Motor's Gross Margin, 2010-2016 - Beiqi Foton Motor's Revenue Breakdown and Gross Margin by Business, 2014-2016 - Heavy Truck Output and Sales Volume of BAIC Group (Beiqi Foton Motor), 2010-2017 - Medium Truck Output and Sales Volume of BAIC Group (Beiqi Foton Motor), 2010-2017 - BAIC Group's Light Truck Output and Sales Volume, 2010-2017 - BAIC Group's Mini Truck Output and Sales Volume, 2010-2017 - Truck Capacity Distribution of Beiqi Foton Motor - Capacity of Beijing Foton Daimler, 2016 - Main Heavy Trucks of Shaanxi Automobile Group - Shaanxi Automobile Group's Heavy Truck Output and Sales Volume, 2010-2017 - Shaanxi Automobile Group's Medium Truck Output and Sales Volume, 2010-2017 - Shaanxi Automobile Group's Light Truck Output and Sales Volume, 2010-2017 - JAC's Revenue and Net Income, 2010-2016 - JAC's Gross Margin, 2010-2016 - JAC's Revenue Structure and Gross Margin by Product, 2016 - JAC's Heavy Truck Output and Sales Volume, 2010-2017 - JAC's Medium Truck Output and Sales Volume, 2010-2017 - JAC's Light Truck Output and Sales Volume, 2010-2017 - Truck Capacity Distribution of JAC, 2016 - Hualing Xingma Automobile's Assets and Net Income, 2012-2016 - Hualing Xingma Automobile's Products Series - Hualing Xingma Automobile's Truck Output and Sales Volume, 2015-2016 - Hualing Xingma Automobile's Truck Sales at Home and Abroad, 2015-2016 - Qingling Motors' Revenue and Net Income, 2010-2016 - Qingling Motors' Gross Margin, 2010-2016 - Qingling Motors' Revenue Breakdown by Product, 2015-2016 - Qingling Motors' Heavy Truck Output and Sales Volume, 2010-2017 - Qingling Motors' Medium Truck Output and Sales Volume, 2010-2017 - Qingling Motors' Light Truck Output and Sales Volume, 2010-2017 - Jiangling Motors' Revenue and Net Income, 2010-2016 - Jiangling Motors' Gross Margin, 2010-2016 - Jiangling Motors' Revenue Structure by Product, 2015-2016 - Jiangling Motors' Light Truck Output and Sales Volume, 2010-2017 - Truck Capacity Distribution of Jiangling Motors, 2016 - Development History of SAIC GM Wuling - Main Trucks (Mini Trucks) of SAIC GM Wuling - SAIC GM Wuling's Mini Truck Output and Sales Volume, 2010-2017 - Distribution of SAIC GM Wuling's Production Bases - SAIC-IVECO Hongyan's Heavy Truck Output and Sales Volume, 2010-2017 - SAIC-IVECO Hongyan's Sales Target, 2017 - Main Heavy Trucks of Hubei Tri-Ring Special Vehicle - Hubei Tri-Ring Special Vehicle's Heavy Truck Output and Sales Volume, 2010-2017 - Hubei Tri-Ring Special Vehicle's Medium Truck Output and Sales Volume, 2010-2017 - Hubei Tri-Ring Special Vehicle's Light Truck Output and Sales Volume, 2010-2017 - XCMG Automobile's Heavy Truck Output and Sales Volume, 2010-2017 - Truck Capacity Distribution of XCMG Automobile, 2016 - GAC Hino Motors' Assets, Liabilities, and Revenue, 2012-2016 - GAC Hino Motors' Heavy Truck Output and Sales Volume, 2010-2017 - GAC Hino Motors' Capacity, 2016 - Zhejiang Feidie Automobile Manufacturing's Heavy Truck Output and Sales Volume, 2010-2017 - Zhejiang Feidie Automobile Manufacturing's Medium Truck Output and Sales Volume, 2010-2017 - Zhejiang Feidie Automobile Manufacturing's Light Truck Output and Sales Volume, 2010-2017 - Baotou Bei Ben Heavy-Duty Truck's Truck Output and Sales Volume, 2010-2017 - Shanxi Dayun Automobile Manufacturing's Heavy Truck Output and Sales Volume, 2010-2017 - Shanxi Dayun Automobile Manufacturing's Medium Truck Output and Sales Volume, 2010-2017 - Shanxi Dayun Automobile Manufacturing's Light Truck Output and Sales Volume, 2010-2017 - Truck Sales Growth in China, 2011-2021E - China's Truck Market Structure, 2010-2021E - Market Share of Top10 Truck Manufacturers in China, 2016 - Beijing Tiantan Biological Products Co., Ltd. (TIANTANBIO) - China Biologic Products, Inc. (NASDAQ: CBPO) - Green Cross China - Guizhou Taibang Biological Products Co., Ltd. - Hualan Biological Engineering,Inc. - Humanwell Healthcare Group Co., Ltd. - Jiangxi Boya Bio-Pharmaceutical Co., Ltd. - Shandong Taibang Biological Products Co., Ltd. - Shanghai Institute of Biological Products Co., Ltd. - Shanghai RAAS Blood Products Co., Ltd. - Shanxi Kangbao Biological Product Co., Ltd. - Shenzhen Weiguang Biological Products Co., Ltd. - Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. - Walvax Biotechnology Co, Ltd. - Xi'an Huitian Blood Products Co., Ltd. - Zhenxing Biopharmaceutical & Chemical Co., Ltd. For more information about this report visit http://www.researchandmarkets.com/research/2dng4t/china_blood Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/china-blood-product-industry-report-2017-product-market-size-expected-to-hit-rmb475-billion-in-2021---research-and-markets-300459175.html


Yin L.,Fudan University | Yin L.,University of Illinois at Urbana - Champaign | Zhao X.,Fudan University | Zhao X.,Shanghai Institute of Biological Products Co. | And 7 more authors.
Biomaterials | Year: 2014

Hypertrophic scar (HS) originates from the over-expression of transforming growth factor β (TGF-β) and downstream SMAD2. With attempts to rectify HS by RNA interference (RNAi) against SMAD2, we report the design of plasmid DNA encoding SMAD2 siRNA (pSUPER-SMAD2), and identify the optimal siRNA sequence toward maximal RNAi efficiency. To realize effective and sustained RNAi, we developed gene activated matrix (GAM) based on porous atelocollagen scaffold and embedded trimethyl chitosan-cysteine (TMCC)/pSUPER-SMAD2 polyplexes for promoting cell growth and gene transfection. The GAM exhibited porosity higher than 80%, pore size of 200-250μm, desired mechanical strength, and sustained pSUPER-SMAD2 release profiles. Normal skin fibroblasts (NSFs) and hypertrophic scar fibroblasts (HSFs) were allowed to infiltrate and proliferate in GAM; at the meantime they were transfected with TMCC/pSUPER-SMAD2 polyplexes to display remarkably reduced SMAD2 levels that lasted for up to 10 days, consequently inhibiting the over-production of type I and type III collagen. We further unraveled the notably higher transfection levels of GAM in three-dimensional (3D) than in 2D environment, which was attributed to the improved cell-matrix interactions that promote cell proliferation and polyplex internalization. This highly safe and effective GAM may serve as a promising candidate towards HS treatment. © 2013 Elsevier Ltd.


PubMed | Shanghai Institute of Biological Products Co. and Shanghai University
Type: | Journal: Electrophoresis | Year: 2017

LB, a bioactive drug, is widely used in treatment of biological diseases. However, due to its poor solution, it is important to find the approach which helps LB to specific biological targets. As the most abundant protein in plasma, HSA plays the role of a carrier of numerous drug ligand. Thus, the interaction between loureirin B (LB) with human serum albumin (HSA) were explored by affinity capillary electrophoresis (ACE), capillary electrophoresis frontal analysis (FA-CE) and pressure-mediated affinity capillary electrophoresis (P-ACE) under simulated physiological conditions (pH = 7.4). The binding constants were calculated as 13.1410


PubMed | Shanghai Institute of Biological Products Co., Nantong University, Shanghai University and Shanghai University of Traditional Chinese Medicine
Type: Journal Article | Journal: Journal of cellular and molecular medicine | Year: 2016

Cardiac fibrosis is a fundamental constituent of a variety of cardiac dysfunction, making it a leading cause of death worldwide. However, no effective treatment for cardiac fibrosis is available. Therefore, novel therapeutics for cardiac fibrosis are highly needed. Recently, miR-19b has been found to be able to protect hydrogen peroxide (H2 O2 )-induced apoptosis and improve cell survival in H9C2 cardiomyocytes, while down-regulation of miR-19b had opposite effects, indicating that increasing miR-19b may be a new therapeutic strategy for attenuating cellular apoptosis during myocardial ischaemia-reperfusion injury. However, considering the fact that microRNAs might exert a cell-specific role, it is highly interesting to determine the role of miR-19b in cardiac fibroblasts. Here, we found that miR-19b was able to promote cardiac fibroblast proliferation and migration. However, miR-19b mimics and inhibitors did not modulate the expression level of collagen I. Pten was identified as a target gene of miR-19b, which was responsible for the effect of miR-19b in controlling cardiac fibroblast proliferation and migration. Our data suggest that the role of miR-19b is cell specific, and systemic miR-19b targeting in cardiac remodelling might be problematic. Therefore, it is highly needed and also urgent to investigate the role of miR-19b in cardiac remodelling in vivo.


PubMed | a National Institutes for Food and Drug Control and Shanghai Institute of Biological Products Co.
Type: | Journal: Human vaccines & immunotherapeutics | Year: 2016

Hepatitis E virus infections have been continuously reported in Indian subcontinent, Africa, southeast and central Asia, posing great health threats to the public, especially to pregnant women. Hecolin is the only licensed HEV vaccine developed by Xiamen Innovax Biotech Co., Ltd. Extensive characterizations on antigenicity, physicochemical properties, efficacy in clinical trials, and manufacturing capability have made Hecolin a promising vaccine for HEV control. However, there are many obstacles in large scale application of Hecolin. Efforts are needed to further evaluate safety and efficacy in HEV risk populations, and to complement HEV standards for quality control. Passing World Health Organization prequalification and licensing outside China are priorities as these are also hindering Hecolin promotion. Multilateral cooperation among Chinese vaccine manufacturers, Chinese National Regulatory Authorization (NRA) and WHO will expedite the entrance of Hecolin into international market, so that Hecolin could play its due role in global hepatitis E control.


Zhou C.,Shanghai Institute of Biological Products Co. | Gu H.,Shanghai Institute of Biological Products Co. | Fan R.,Shanghai Institute of Biological Products Co. | Wang B.,Shanghai Institute of Biological Products Co. | Lou J.,Shanghai Institute of Biological Products Co.
Stem Cells and Development | Year: 2015

Recent studies suggest that mature somatic cells can be reprogrammed to become induced pluripotent stem cells by overexpressing specific transcription factors or microRNAs (miRNAs). Theoretically, this technique could provide a wide array of cells for therapeutics. However, the process of redifferentiation after cell reprogramming to pluripotency is inefficient and time restricted. We proposed that the differentiation of somatic cells into specific cells of another germ layer can be induced and accelerated with appropriate miRNAs and culture conditions. In human fibroblasts, we found that overexpression of pluripotency stem cell-specific miRNA-302/367 cluster, together with two other neuron-specific miRNAs (miRNA-9/9∗ and miRNA-124) induced fibroblasts conversion into neurons. The cells assumed neuron morphology, were positive for several neuron markers, and exhibited neuronal membrane potential feature. Moreover, concentrated expression of synaptic markers were observed in these cells in vitro and in vivo in nude mice brain, suggesting possible connectivity. To achieve efficient reprogramming, miRNA-302/367 cluster, miRNA-9/9∗, and miRNA-124 were all required. The combination of the proved pluripotency-inducing miRNA-302/367 cluster and cell-specific miRNAs provides a unique strategy for one-step cellular conversion that could have important implications for studies of neuron development and neurological disease therapy. © 2015, Mary Ann Liebert, Inc. 2015.


Huang D.,East China University of Science and Technology | Xia-Hou K.,East China University of Science and Technology | Liu X.-P.,East China University of Science and Technology | Zhao L.,East China University of Science and Technology | And 5 more authors.
Vaccine | Year: 2014

Influenza vaccine production using cell culture technology has become popular nowadays. However, to meet the ever increasing demand of influenza vaccine, it is prerequisite to improve the yield of influenza virus in cells. To achieve this, in the present study, the nutritional requirements of MDCK cells in the virus production process were analyzed and a nutrient-feeding strategy was developed accordingly. Based on the consumption rates and corresponding concentration optimization, glucose and fast metabolized amino acids were supplemented into the maintaining medium at the time of infection. Compared with the non-supplemented culture, the average cell specific death rate during 0-48h post-infection was 0.013h-1, which was 40.91% lower in the nutrient-supplemented culture. Total virus titer, HA antigen protein concentration and cell-specific virus yield were (1.88±0.23)×103HAunits/50μL, 11.70±0.22μg/mL and (10.06±1.16)×103virions/cell, respectively, which were 84.04±22.50%, 31.46±2.87% and 86.64±25.81% higher than those in the control, respectively. These data showed that the appropriate supplementation of nutrients during virus production process could reduce cell death, and improve cell-specific virus yield and total influenza virus output. This study laid foundation for the development of cell culture technology for influenza vaccine production. © 2014 Elsevier Ltd.


Wu G.-P.,Shanghai Institute of Biological Products Co. | Zhu W.,Shanghai Institute of Biological Products Co.
Chinese Journal of Biologicals | Year: 2016

Varicella-zoster virus (VZV) is the pathogen of varicella (chicken pox) and herpes zoster (shingles,HZ), with a high infectivity and morbidity. VZV-Oka strain is the only strain used for vaccine production recommended by the WHO. The effectiveness and safety of varicella vaccine have been confirmed in post-marketing application. Meanwhile, HZ vaccines are under development by many pharmaceutical companies. This paper reviews the epidemiology of VZV and development of vaccines.


PubMed | Shanghai Institute of Biological Products Co.
Type: Journal Article | Journal: Stem cells and development | Year: 2015

Recent studies suggest that mature somatic cells can be reprogrammed to become induced pluripotent stem cells by overexpressing specific transcription factors or microRNAs (miRNAs). Theoretically, this technique could provide a wide array of cells for therapeutics. However, the process of redifferentiation after cell reprogramming to pluripotency is inefficient and time restricted. We proposed that the differentiation of somatic cells into specific cells of another germ layer can be induced and accelerated with appropriate miRNAs and culture conditions. In human fibroblasts, we found that overexpression of pluripotency stem cell-specific miRNA-302/367 cluster, together with two other neuron-specific miRNAs (miRNA-9/9* and miRNA-124) induced fibroblasts conversion into neurons. The cells assumed neuron morphology, were positive for several neuron markers, and exhibited neuronal membrane potential feature. Moreover, concentrated expression of synaptic markers were observed in these cells in vitro and in vivo in nude mice brain, suggesting possible connectivity. To achieve efficient reprogramming, miRNA-302/367 cluster, miRNA-9/9*, and miRNA-124 were all required. The combination of the proved pluripotency-inducing miRNA-302/367 cluster and cell-specific miRNAs provides a unique strategy for one-step cellular conversion that could have important implications for studies of neuron development and neurological disease therapy.


PubMed | East China University of Science and Technology and Shanghai Institute of Biological Products Co.
Type: Journal Article | Journal: PloS one | Year: 2015

Development of serum-free suspension cell culture processes is very important for influenza vaccine production. Previously, we developed a MDCK suspension cell line in a serum-free medium. In the present study, the growth kinetics of suspension MDCK cells and influenza virus production in the serum-free medium were investigated, in comparison with those of adherent MDCK cells in both serum-containing and serum-free medium. It was found that the serum-free medium supported the stable subculture and growth of both adherent and suspension cells. In batch culture, for both cell lines, the growth kinetics in the serum-free medium was comparable with those in the serum-containing medium and a commercialized serum-free medium. In the serum-free medium, peak viable cell density (VCD), haemagglutinin (HA) and median tissue culture infective dose (TCID50) titers of the two cell lines reached 4.51106 cells/mL, 2.94Log10(HAU/50 L) and 8.49Log10(virions/mL), and 5.97106 cells/mL, 3.88Log10(HAU/50 L), and 10.34Log10(virions/mL), respectively. While virus yield of adherent cells in the serum-free medium was similar to that in the serum-containing medium, suspension culture in the serum-free medium showed a higher virus yield than adherent cells in the serum-containing medium and suspension cells in the commercialized serum-free medium. However, the percentage of infectious viruses was lower for suspension culture in the serum-free medium. These results demonstrate the great potential of this suspension MDCK cell line in serum-free medium for influenza vaccine production and further improvements are warranted.

Loading Shanghai Institute of Biological Products Co. collaborators
Loading Shanghai Institute of Biological Products Co. collaborators